Strategically combining these trafficking-directed therapies with conventional PD-1/PD-L1 inhibitors may provide synergistic benefits by blocking ligand–receptor interactions and limiting total PD-L1 availability, potentially overcoming adaptive resistance and enhancing durable responses across diverse cancer types. The gene discussed is CD274; the disease is cancer.